Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. [Operator ...

The firm discussed the development of anti-TL1A antagonist duvakitug beyond just inflammatory ... for the shares is justified amid Teva’s growing brand neuropsychiatry sales footprint and ...

The DARI program, as I mentioned, is our biggest Phase 3 study to date at Teva. And we really got a good head start on our site initiations. Duvakitug ... of these legacy brands and generics ...

Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Teva Pharmaceuticals Industries Ltd TEVA is ... including the positive Phase 2b results for our duvakitug (anti-Tl1A) asset. These results pave the way for pivotal trials in Crohn's disease ...

In the U.S., Dupixent continued its leadership in New to Brand prescriptions across ... On Slide 22, our partner Teva recently announced positive duvakitug Phase 2b results in IBD.

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.

Teva Pharmaceutical Industries Ltd. (NYSE ... including the positive Phase 2b results for our duvakitug (anti-Tl1A) asset. These results pave the way for pivotal trials in Crohn's disease and ...